Published in J Virol on January 01, 2002
Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol (2002) 2.98
Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice. J Virol (2005) 2.22
Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol (2005) 2.05
Heterologous gene expression from transmissible gastroenteritis virus replicon particles. J Virol (2002) 1.85
Norovirus capture with histo-blood group antigens reveals novel virus-ligand interactions. J Virol (2004) 1.80
A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology (2007) 1.74
Norovirus GII.4 strain antigenic variation. J Virol (2010) 1.73
Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. PLoS Pathog (2008) 1.69
Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol (2007) 1.24
Norwalk virus-like particles as vaccines. Expert Rev Vaccines (2010) 1.23
Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol (2009) 1.17
High-resolution x-ray structure and functional analysis of the murine norovirus 1 capsid protein protruding domain. J Virol (2010) 1.13
Comparison of immune responses to gonococcal PorB delivered as outer membrane vesicles, recombinant protein, or Venezuelan equine encephalitis virus replicon particles. Infect Immun (2005) 0.99
Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. Vaccine (2008) 0.99
Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus. Nanomedicine (Lond) (2012) 0.99
Characterization of blockade antibody responses in GII.2.1976 Snow Mountain virus-infected subjects. J Virol (2013) 0.98
Glycosphingolipids as receptors for non-enveloped viruses. Viruses (2010) 0.98
Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus. J Virol (2011) 0.96
Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node. J Immunol (2008) 0.92
The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine (2008) 0.92
Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. Vaccine (2010) 0.92
Vaccination of mice with gonococcal TbpB expressed in vivo from Venezuelan equine encephalitis viral replicon particles. Infect Immun (2006) 0.92
Identification of cross-reactive norovirus CD4+ T cell epitopes. J Virol (2010) 0.91
Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles. Vaccine (2012) 0.88
Comparative evaluation of recombinant protein production in different biofactories: the green perspective. Biomed Res Int (2014) 0.86
Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis. Breast Cancer Res (2004) 0.85
Alphavirus-based vaccines. Viruses (2014) 0.84
Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses. J Virol (2014) 0.83
Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives. Future Virol (2015) 0.82
A human dendritic cell subset receptive to the Venezuelan equine encephalitis virus-derived replicon particle constitutively expresses IL-32. J Immunol (2008) 0.79
Vaccine against norovirus. Hum Vaccin Immunother (2014) 0.79
Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle. Virol J (2013) 0.77
Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition. Clin Vaccine Immunol (2015) 0.77
Food-related illness and death in the United States. Emerg Infect Dis (1999) 39.22
Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol (1992) 8.35
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
X-ray crystallographic structure of the Norwalk virus capsid. Science (1999) 6.58
Sequence and genomic organization of Norwalk virus. Virology (1993) 6.25
Molecular epidemiology of "Norwalk-like viruses" in outbreaks of gastroenteritis in the United States. J Infect Dis (1998) 5.32
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology (1997) 3.62
The epidemiology of enteric caliciviruses from humans: a reassessment using new diagnostics. J Infect Dis (2000) 3.29
Norwalk virus open reading frame 3 encodes a minor structural protein. J Virol (2000) 2.96
Genetic polymorphism across regions of the three open reading frames of "Norwalk-like viruses". Arch Virol (2000) 2.84
Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology (1998) 2.81
Molecular epidemiology of human enteric caliciviruses in The Netherlands. J Infect Dis (2000) 2.69
Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis (1990) 2.63
Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology (2000) 2.59
Proteins of Norwalk virus. J Virol (1981) 2.59
Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations. J Clin Microbiol (1993) 2.58
Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology (1999) 2.54
Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone. Virology (1991) 2.13
Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol (2000) 2.09
Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis (2000) 2.02
Antigenic mapping of the recombinant Norwalk virus capsid protein using monoclonal antibodies. Virology (1996) 2.01
Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci U S A (1996) 2.00
Vaccination strategies for mucosal immune responses. Clin Microbiol Rev (2001) 1.98
Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine (2000) 1.95
Organization and expression of calicivirus genes. J Infect Dis (2000) 1.94
Biochemical characterization of a smaller form of recombinant Norwalk virus capsids assembled in insect cells. J Virol (1997) 1.80
Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol (1998) 1.80
Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol (1997) 1.73
Capsid protein diversity among Norwalk-like viruses. Virus Genes (2000) 1.72
Specific proteolytic cleavage of recombinant Norwalk virus capsid protein. J Virol (1995) 1.69
A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J Virol (1996) 1.68
Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology (1995) 1.65
Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol (2001) 1.59
Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. Virology (1995) 1.57
Altered phosphorylation pattern of simian virus 40 T antigen expressed in insect cells by using a baculovirus vector. J Virol (1990) 1.51
Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun (1997) 1.38
Alphavirus vectors for gene expression and vaccines. Curr Opin Biotechnol (1999) 1.34
Mucosal immunity induced by parenteral immunization with a live attenuated Venezuelan equine encephalitis virus vaccine candidate. Virology (1997) 1.22
Transmission of Norwalk virus during football game. N Engl J Med (2000) 1.22
Norwalk virus vaccines: challenges and progress. J Infect Dis (2000) 1.20
Immunity to calicivirus infection. J Infect Dis (2000) 1.17
Virus-like particles as a rotavirus subunit vaccine. J Infect Dis (1996) 1.12
Complete nucleotide sequence of the chiba virus genome and functional expression of the 3C-like protease in Escherichia coli. Virology (2000) 1.11
Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine (2000) 1.08
Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice. Vaccine (1997) 1.04
Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine (1999) 1.03
Structure of O-glycosidically linked oligosaccharides synthesized by the insect cell line Sf9. J Cell Biochem (1990) 0.99
Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine (1999) 0.99
Papillomavirus-like particle vaccines for cervical cancer. Mol Med Today (1999) 0.99
Alphavirus expression vectors and their use as recombinant vaccines: a minireview. Gene (1997) 0.99
Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles. J Virol (1999) 0.98
Nucleocapsid- and virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and the S segments of Hantaan virus. Virus Res (1995) 0.95
Norwalk-like viral gastroenteritis outbreak in U.S. Army trainees. Emerg Infect Dis (2000) 0.94
Genomic diversity of "Norwalk like viruses" (NLVs): pediatric infections in a Brazilian shantytown. J Med Virol (1999) 0.92
Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine (2000) 0.89
Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques. Intervirology (1996) 0.88
Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. Virology (1996) 0.86
Norwalk virus infection in Venezuela. Ann Trop Med Parasitol (1998) 0.82
Glycosylation of synthetic T helper cell epitopic peptides influences their antigenic potency and conformation in a sugar location-specific manner. Biochim Biophys Acta (1994) 0.81
Posttranslational side chain modification of a viral epitope results in diminished recognition by specific T cells. J Virol (1992) 0.81
Differences in the post-translational modifications of human papillomavirus type 6b major capsid protein expressed from a baculovirus system compared with a vaccinia virus system. Biotechnol Appl Biochem (2000) 0.81
The effects of post-translational side-chain modifications on the stimulatory activity, serum stability and conformation of synthetic peptides carrying T helper cell epitopes. Biochim Biophys Acta (1996) 0.80
A new model system to study Norwalk virus immunity. Gastroenterology (1999) 0.79
Human susceptibility and resistance to Norwalk virus infection. Nat Med (2003) 7.07
Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol (2013) 4.98
Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med (2008) 4.57
Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J Virol (2002) 4.29
Norwalk virus: how infectious is it? J Med Virol (2008) 3.93
Genetic analysis of complex traits in the emerging Collaborative Cross. Genome Res (2011) 3.25
Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol (2002) 2.98
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82
A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog (2007) 2.71
Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. J Virol (2009) 2.60
Cellular and humoral immunity following Snow Mountain virus challenge. J Virol (2005) 2.59
Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol (2010) 2.53
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42
Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice. J Virol (2005) 2.22
Clinical and economic outcomes of the electronic intensive care unit: results from two community hospitals. Crit Care Med (2010) 2.22
Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol (2003) 2.20
Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol (2007) 2.18
Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A (2014) 2.17
Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol (2005) 2.05
Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog (2012) 2.02
Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. Proc Natl Acad Sci U S A (2008) 1.97
Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol Rev (2008) 1.96
A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol (2013) 1.94
Heterologous gene expression from transmissible gastroenteritis virus replicon particles. J Virol (2002) 1.85
Norovirus capture with histo-blood group antigens reveals novel virus-ligand interactions. J Virol (2004) 1.80
Unique signatures of long noncoding RNA expression in response to virus infection and altered innate immune signaling. MBio (2010) 1.79
Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med (2006) 1.78
Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol (2007) 1.75
Evidence supporting a zoonotic origin of human coronavirus strain NL63. J Virol (2012) 1.75
Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine (2006) 1.74
Norovirus GII.4 strain antigenic variation. J Virol (2010) 1.73
Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2013) 1.73
Epidemiology and drinking water: are we running dry? Epidemiology (2003) 1.73
The nsp2 replicase proteins of murine hepatitis virus and severe acute respiratory syndrome coronavirus are dispensable for viral replication. J Virol (2005) 1.71
Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol (2009) 1.70
Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. PLoS Pathog (2008) 1.69
Antibody is critical for the clearance of murine norovirus infection. J Virol (2008) 1.69
Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol (2013) 1.68
Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog (2010) 1.67
Impact of a school-based hygiene promotion and sanitation intervention on pupil hand contamination in Western Kenya: a cluster randomized trial. Am J Trop Med Hyg (2012) 1.60
Expression and self-assembly of norwalk virus capsid protein from venezuelan equine encephalitis virus replicons. J Virol (2002) 1.60
Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol (2009) 1.58
Effects of PKR/RNase L-dependent and alternative antiviral pathways on alphavirus replication and pathogenesis. Viral Immunol (2002) 1.56
Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog (2010) 1.56
Single-amino-acid substitutions in open reading frame (ORF) 1b-nsp14 and ORF 2a proteins of the coronavirus mouse hepatitis virus are attenuating in mice. J Virol (2005) 1.54
Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol (2011) 1.53
Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J Virol (2009) 1.51
Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc Natl Acad Sci U S A (2006) 1.49
Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J Infect Dis (2013) 1.47
MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog (2008) 1.47
Golden hamsters are nocturnal in captivity but diurnal in nature. Biol Lett (2008) 1.44
Modeling host genetic regulation of influenza pathogenesis in the collaborative cross. PLoS Pathog (2013) 1.43
Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio (2013) 1.41
Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life (2002) 1.41
Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med (2006) 1.40
Norovirus immunity and the great escape. PLoS Pathog (2012) 1.40
Mitigating medical identity theft. J AHIMA (2008) 1.37
Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol (2012) 1.36
An attenuating mutation in nsP1 of the Sindbis-group virus S.A.AR86 accelerates nonstructural protein processing and up-regulates viral 26S RNA synthesis. J Virol (2003) 1.35
Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol Ther (2009) 1.35
Expression quantitative trait Loci for extreme host response to influenza a in pre-collaborative cross mice. G3 (Bethesda) (2012) 1.35
SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Virol (2012) 1.33
Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. J Virol (2004) 1.32
Cleavage between replicase proteins p28 and p65 of mouse hepatitis virus is not required for virus replication. J Virol (2004) 1.32
SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog (2010) 1.32
Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J Virol (2011) 1.29
A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med (2012) 1.26
Norovirus infectivity in humans and persistence in water. Appl Environ Microbiol (2011) 1.26
Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol (2007) 1.24
SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium. Virus Res (2007) 1.24
Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis (2013) 1.23
Systematic assembly of a full-length infectious clone of human coronavirus NL63. J Virol (2008) 1.23
Characterization of the homo- and heterotypic immune responses after natural norovirus infection. J Med Virol (2005) 1.23
Processing of open reading frame 1a replicase proteins nsp7 to nsp10 in murine hepatitis virus strain A59 replication. J Virol (2007) 1.22
Rewiring the severe acute respiratory syndrome coronavirus (SARS-CoV) transcription circuit: engineering a recombination-resistant genome. Proc Natl Acad Sci U S A (2006) 1.22
A novel viral system for generating antigen-specific T cells. J Immunol (2005) 1.21
Venezuelan equine encephalitis virus disrupts STAT1 signaling by distinct mechanisms independent of host shutoff. J Virol (2009) 1.19
Retracted Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A (2014) 1.19
Presentation, treatment, and outcomes of dural metastases in men with metastatic castrate-resistant prostate cancer: a case series. J Palliat Med (2010) 1.18
Effect of a community-based nursing intervention on mortality in chronically ill older adults: a randomized controlled trial. PLoS Med (2012) 1.18
Characterization of emerging GII.g/GII.12 noroviruses from a gastroenteritis outbreak in the United States in 2010. J Clin Microbiol (2011) 1.18